Cyto Pulse Sciences, Inc. And The Center For Vaccine Development Received IRB Approval For A Phase I Tolerability Study Of Easy Vax
2/11/2009 9:42:57 AM
GLEN BURNIE, Md.--(BUSINESS WIRE)--Cyto Pulse Sciences, a leading developer of tolerable, electric field based, intradermal and epidermal DNA vaccine delivery devices, today announced ethical committee approval for the Phase I medical device study to investigate the safety and tolerability of the Easy Vax™ Clinical Epidermal Electroporation System in healthy volunteers. The study, funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, will be conducted by investigators at the Center for Vaccine Development, University of Maryland School of Medicine.
comments powered by